MCID: PMS001
MIFTS: 58

Poems Syndrome

Categories: Blood diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Poems Syndrome

MalaCards integrated aliases for Poems Syndrome:

Name: Poems Syndrome 12 74 52 58 54 43 15 17 71
Crow-Fukase Syndrome 52 58 36
Osteosclerotic Myeloma 58 71
Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome 52
Polyneuropathy-Endocrinopathy-Plasma Cell Dyscrasia Syndrome 58
Polyneuropathy Organomegaly 52
Takatsuki Syndrome 58
Pep Syndrome 58

Characteristics:

Orphanet epidemiological data:

58
poems syndrome
Age of onset: Adult,Elderly; Age of death: adult,elderly,normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Poems Syndrome

KEGG : 36 Crow-Fukase syndrome, also called POEMS syndrome, is a rare paraneoplastic syndrome due to an underlying plasma cell neoplasm, characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes as its salient features. Major diagnostic criteria include sclerotic bone lesions, elevated serum or plasma levels of vascular endothelial growth factor (VEGF), and Castleman disease. The misdiagnosis is very common due to its rarity and complicated clinical manifestations. Recognition of the complex of clinical complications is the first step in effectively managing the disease. The pathogenesis is not well understood. VEGF appears to play an important role in the disease and is especially useful for monitoring therapy, but it is not likely the sole factor driving the disease. The most commonly used therapies include alkylators and steroids, high-dose chemotherapy with peripheral blood stem cell transplantation, lenalidomide, and bortezomib.

MalaCards based summary : Poems Syndrome, also known as crow-fukase syndrome, is related to glomeruloid hemangioma and plasma cell neoplasm. An important gene associated with Poems Syndrome is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lenalidomide and Ichthammol have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and endothelial, and related phenotypes are polyneuropathy and hypogonadism

Disease Ontology : 12 A blood protein disease that is characterized by polyneuropathy, oranomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, especially hyperpigmentation.

NIH Rare Diseases : 52 POEMS syndrome is a rare, mulitisystem disorder. POEMS stands for the disorder's features, which may include P olyneuropathy , O rganomegaly , E ndocrinopathy , M onoclonal gammopathy , and S kin changes. Signs and symptoms may include progressive sensorimotor polyneuropathy ; enlarged liver, spleen, and/or lymph nodes ; a disorder of the endocrine glands (often with multiple abnormalities); a monoclonal plasma cell proliferative disorder; and darkening of the skin (hyperpigmentation). Various other symptoms may also occur and may vary among affected people. The underlying cause of the disorder is not well understood. POEMS syndrome is a chronic disorder, with a median survival time of 8-14 years. There is no standard treatment; management depends on the underlying plasma cell disorder and may include radiation therapy , chemotherapy , and/or hematopoietic cell transplantation.

Wikipedia : 74 POEMS syndrome (also termed osteosclerotic myeloma, Crow-Fukase syndrome, Takatsuki disease, or PEP... more...

Related Diseases for Poems Syndrome

Diseases related to Poems Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 691)
# Related Disease Score Top Affiliating Genes
1 glomeruloid hemangioma 32.9 VEGFA MYOM2 IL6
2 plasma cell neoplasm 31.6 VEGFA MYOM2 IL6
3 castleman disease 31.2 VEGFA IL6 CSF3
4 polyneuropathy 31.2 VEGFA TNF IL6 IL1B EPO
5 osteosclerotic myeloma 31.0 VEGFA MYOM2 IL6 IL1B
6 thrombocytosis 30.8 IL6 IL1B EPO CSF3
7 pulmonary hypertension 30.7 VEGFA TNF IL6 IL1B
8 plasmacytoma 30.7 VEGFA IL6 IL2
9 macular retinal edema 30.6 VEGFA TNF IL6
10 vasculitis 30.5 TNF PTX3 IL6
11 carotid stenosis 30.3 VEGFA TNFRSF11B TNF
12 paraneoplastic syndromes 30.3 IL6 CSF3
13 extramedullary plasmacytoma 30.3 MYOM2 IL6
14 polyradiculopathy 30.2 TNF IL6 IL1B
15 varicose veins 30.1 VEGFA TNF IL6
16 monoclonal gammopathy of uncertain significance 30.1 TNFSF11 TNF MYOM2 IL6
17 aortitis 30.1 TNF IL6
18 optic nerve disease 30.1 VEGFA TNF IL6
19 indolent myeloma 30.0 MYOM2 IL6 IL1B
20 hypothyroidism 30.0 VEGFA TNFRSF11B TNF IL2
21 pericarditis 29.9 TNF IL6 IL1B
22 congestive heart failure 29.9 VEGFA TNF IL6 EPO
23 ileus 29.9 TNF IL6 IL1B
24 familial mediterranean fever 29.9 TNF IL6 IL1B
25 lyme disease 29.9 TNF IL6 IL1B
26 polyclonal hypergammaglobulinemia 29.9 MYOM2 IL6
27 retinal detachment 29.9 VEGFA TNF IL6 EPO
28 hyperparathyroidism 29.8 TNFSF11 TNFRSF11B EPO
29 capillary leak syndrome 29.8 IL6 IL2 CSF3
30 pancytopenia 29.7 IL6 EPO CSF3
31 thyroiditis 29.6 TNF IL6 IL2
32 peritonitis 29.6 TNF IL6 IL1B CSF3
33 diffuse large b-cell lymphoma 29.6 VEGFA TNF IL6 CSF3
34 bone resorption disease 29.5 TNFSF11 TNFRSF11B TNF IL6
35 peripheral nervous system disease 29.5 VEGFA TNF MYOM2 IL6 IL2 IL1B
36 respiratory failure 29.4 TNF PTX3 IL6 IL1B EPO
37 orchitis 29.4 TNF IL6 IL2
38 end stage renal failure 29.4 TNF IL6 IL2 EPO
39 uveitis 29.4 TNF IL6 IL2
40 localized scleroderma 29.3 TNF IL6 IL2
41 osteonecrosis 29.3 VEGFA TNFSF11 TNFRSF11B TNF
42 exanthem 29.2 VEGFA TNF IL6 IL2 CSF3
43 sleep apnea 29.2 VEGFA TNF IL6 IL1B EPO
44 diarrhea 29.1 TNF IL6 IL2 IL1B CSF3
45 kidney disease 29.1 VEGFA TNFRSF11B TNF IL6 HGF EPO
46 arthritis 29.1 VEGFA TNFSF11 TNF IL6 IL1B
47 pulmonary edema 29.1 TNF IL1B HGF EPO CSF3
48 hashimoto thyroiditis 29.0 TNF IL6 IL2 IL1B
49 myositis 29.0 TNF IL6 IL2 IL1B
50 demyelinating disease 29.0 TNF IL6 IL2 IL1B

Graphical network of the top 20 diseases related to Poems Syndrome:



Diseases related to Poems Syndrome

Symptoms & Phenotypes for Poems Syndrome

Human phenotypes related to Poems Syndrome:

58 31 (show all 47)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 polyneuropathy 58 31 obligate (100%) Obligate (100%) HP:0001271
2 hypogonadism 58 31 hallmark (90%) Very frequent (99-80%) HP:0000135
3 lymphoproliferative disorder 58 31 hallmark (90%) Very frequent (99-80%) HP:0005523
4 visceromegaly 58 31 hallmark (90%) Very frequent (99-80%) HP:0003271
5 increased antibody level in blood 58 31 hallmark (90%) Very frequent (99-80%) HP:0010702
6 abnormality of skin physiology 58 31 hallmark (90%) Very frequent (99-80%) HP:0011122
7 diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0000819
8 hypothyroidism 58 31 frequent (33%) Frequent (79-30%) HP:0000821
9 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
10 ascites 58 31 frequent (33%) Frequent (79-30%) HP:0001541
11 pulmonary arterial hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0002092
12 areflexia 58 31 frequent (33%) Frequent (79-30%) HP:0001284
13 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
14 thickened skin 58 31 frequent (33%) Frequent (79-30%) HP:0001072
15 erectile abnormalities 58 31 frequent (33%) Frequent (79-30%) HP:0100639
16 paresthesia 58 31 frequent (33%) Frequent (79-30%) HP:0003401
17 primary adrenal insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0008207
18 pain 58 31 frequent (33%) Frequent (79-30%) HP:0012531
19 thrombocytosis 58 31 frequent (33%) Frequent (79-30%) HP:0001894
20 papilledema 58 31 frequent (33%) Frequent (79-30%) HP:0001085
21 hemangioma 58 31 frequent (33%) Frequent (79-30%) HP:0001028
22 gynecomastia 58 31 frequent (33%) Frequent (79-30%) HP:0000771
23 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
24 hyperpigmentation of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0000953
25 hypertrichosis 58 31 frequent (33%) Frequent (79-30%) HP:0000998
26 pleural effusion 58 31 frequent (33%) Frequent (79-30%) HP:0002202
27 clubbing of fingers 58 31 frequent (33%) Frequent (79-30%) HP:0100759
28 pericardial effusion 58 31 frequent (33%) Frequent (79-30%) HP:0001698
29 sclerotic vertebral endplates 58 31 frequent (33%) Frequent (79-30%) HP:0004576
30 leukonychia 58 31 frequent (33%) Frequent (79-30%) HP:0001820
31 sclerosis of skull base 58 31 frequent (33%) Frequent (79-30%) HP:0002694
32 metaphyseal sclerosis 58 31 frequent (33%) Frequent (79-30%) HP:0004979
33 sclerosis of hand bone 58 31 frequent (33%) Frequent (79-30%) HP:0004054
34 sclerosis of foot bone 58 31 frequent (33%) Frequent (79-30%) HP:0100925
35 acrocyanosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001063
36 respiratory insufficiency due to muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0002747
37 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936
38 lipodystrophy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009125
39 arterial thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004420
40 polycythemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001901
41 hyperesthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100963
42 restrictive deficit on pulmonary function testing 58 31 occasional (7.5%) Occasional (29-5%) HP:0002111
43 increased circulating prolactin concentration 31 occasional (7.5%) HP:0000870
44 muscle weakness 58 Frequent (79-30%)
45 abnormality of the endocrine system 58 Very frequent (99-80%)
46 edema 58 Frequent (79-30%)
47 prolactin excess 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Poems Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 CSF3 EPO HGF IL1B IL2 IL6
2 immune system MP:0005387 10.02 CSF3 EPO IL1B IL2 IL6 PTX3
3 cardiovascular system MP:0005385 10.01 EPO HGF IL1B IL2 IL6 TNF
4 integument MP:0010771 9.8 CSF3 EPO IL1B IL6 TNF TNFSF11
5 liver/biliary system MP:0005370 9.63 EPO HGF IL2 IL6 TNF VEGFA
6 neoplasm MP:0002006 9.43 IL1B IL2 IL6 TNF TNFSF11 VEGFA
7 respiratory system MP:0005388 9.17 EPO IL2 IL6 PTX3 TNF TNFSF11

Drugs & Therapeutics for Poems Syndrome

Drugs for Poems Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenalidomide Approved Phase 2 191732-72-6 216326
2
Ichthammol Approved Phase 2 8029-68-3
3
Ixazomib Approved, Investigational Phase 2 1072833-77-2
4
Sodium citrate Approved, Investigational Phase 2 68-04-2
5
rituximab Approved Phase 2 174722-31-7 10201696
6
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
8
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
9
Etoposide Approved Phase 2 33419-42-0 36462
10
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12
Melphalan Approved Phase 2 148-82-3 4053 460612
13
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
14
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
16
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750
17
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
18
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
19 Neurotransmitter Agents Phase 2
20 Citrate Phase 2
21 Anticoagulants Phase 2
22 Chelating Agents Phase 2
23 Calcium, Dietary Phase 2
24 Antibodies, Monoclonal Phase 2
25 Antineoplastic Agents, Immunological Phase 2
26 Immunoglobulins Phase 2
27 Antibodies Phase 2
28 Antiemetics Phase 2
29 Immunologic Factors Phase 2
30 HIV Protease Inhibitors Phase 2
31
protease inhibitors Phase 2
32 Gastrointestinal Agents Phase 2
33 Angiogenesis Inhibitors Phase 2
34 BB 1101 Phase 2
35 Autonomic Agents Phase 2
36 Hormone Antagonists Phase 2
37 Anti-Inflammatory Agents Phase 2
38 Antineoplastic Agents, Hormonal Phase 2
39 glucocorticoids Phase 2
40 Hormones Phase 2
41 Alkylating Agents Phase 2
42 Anti-Infective Agents Phase 2
43 Antibiotics, Antitubercular Phase 2
44 Topoisomerase Inhibitors Phase 2
45 Anti-Bacterial Agents Phase 2
46
Liposomal doxorubicin Phase 2 31703
47 Antirheumatic Agents Phase 2
48 Immunosuppressive Agents Phase 2
49 Etoposide phosphate Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2 Lenalidomide and dexamethasone
2 Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome Completed NCT02193698 Phase 2 Lenalidomide+Dexamethasone
3 An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome Completed NCT01816620 Phase 2 Lenalidomide, Dexamethasone
4 Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. Completed NCT01639898 Phase 2 Lenalidomide and dexamethasone;Lenalidomide and dexamethasone
5 Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome Recruiting NCT02921893 Phase 2 Dexamethasone;Ixazomib Citrate;Lenalidomide
6 An Open, One-arm, Prospective Study of a Single Dose Anti-CD20 Monoclonal Antibody Combined With Bortezomib for Treatment of Relapsed Refractory Autoimmune Hemolytic Anemia Recruiting NCT04083014 Phase 2 combination of a single dose anti-CD20 antibody and bortezomib
7 Tandem Autotransplantation for Multiple Myeloma in Participants With Less Than 12 Months of Preceding Therapy, Incorporating Velcade (Bortezomib) With the Transplant Chemotherapy and During Maintenance Terminated NCT01548573 Phase 2 Dexamethasone;Cisplatin;Doxorubicin;Cyclophosphamide;Etoposide;Bortezomib;Thalidomide;Melphalan
8 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844

Search NIH Clinical Center for Poems Syndrome

Cochrane evidence based reviews: poems syndrome

Genetic Tests for Poems Syndrome

Anatomical Context for Poems Syndrome

MalaCards organs/tissues related to Poems Syndrome:

40
Skin, Bone, Endothelial, Lymph Node, Liver, Spleen, B Cells

Publications for Poems Syndrome

Articles related to Poems Syndrome:

(show top 50) (show all 1092)
# Title Authors PMID Year
1
POEMS syndrome with idiopathic portal hypertension: autopsy case and review of the literature. 54 61
20403034 2010
2
[Advances and perspectives in treatment for refractory neuropathies with special reference to immune-mediated neuropathies and Crow-Fukase syndrome]. 54 61
20411803 2010
3
[Crow-Fukase (POEMS) syndrome]. 54 61
20420180 2010
4
POEMS syndrome complicated by follicular lymphoma. 54 61
20009437 2009
5
Relapse of POEMS syndrome without increased level of VEGF. 54 61
19720532 2009
6
Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation. 54 61
19269178 2009
7
Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. 54 61
19289745 2009
8
Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation. 54 61
18660839 2008
9
Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. 54 61
18469028 2008
10
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. 54 61
18843731 2008
11
[Crow-Fukase syndrome and VEGF]. 54 61
18567356 2008
12
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. 54 61
18567358 2008
13
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. 54 61
18221391 2008
14
VEGF and osteosclerosis in POEMS syndrome. 54 61
18172647 2008
15
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome. 54 61
17895817 2007
16
[POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation]. 54 61
17867301 2007
17
Expression of vascular endothelial growth factor by plasma cells in the sclerotic bone lesion of a patient with POEMS syndrome. 54 61
17277913 2007
18
[Blood cytokine levels as a clinical laboratory test]. 54 61
17441472 2007
19
Increased expression of vascular endothelial growth factor and its receptor, Flt-1, in glomeruloid haemangioma associated with Crow-Fukase syndrome. 54 61
17309484 2007
20
Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. 54 61
17077605 2006
21
Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue. 54 61
16926143 2006
22
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. 54 61
16879774 2006
23
Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. 54 61
16564945 2006
24
Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. 54 61
15975949 2005
25
A case of POEMS syndrome with cystoid macular edema. 54 61
15767082 2005
26
[Highly concentrated vascular endothelial growth factor in Crow-Fukase syndrome with high output heart failure: a case report]. 54 61
15768610 2005
27
POEMS syndrome demonstrating VEGF decrease by ticlopidine. 54 61
15609708 2004
28
POEMS syndrome and VEGF. 54 61
15609693 2004
29
No nephropathy in Type 2 diabetic patient with POEMS syndrome with an elevated plasma VEGF. 54 61
15008843 2004
30
Multiple vascular abnormalities and a paradoxical combination of vitamin B12 deficiency and thrombocytosis in a case with POEMS syndrome. 54 61
14673584 2003
31
Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome. 54 61
14714967 2003
32
[A case of anaphylactoid shock occurring immediately after the initiation of second intravenous administration of high-dose immunoglobulin (IVIg) in a patient with Crow-Fukase syndrome]. 54 61
14503355 2003
33
POEMS syndrome associated with ischemic stroke. 54 61
12756139 2003
34
[A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]. 54 61
12884826 2003
35
Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. 54 61
12521215 2002
36
Crow-Fukase syndrome associated with high-output heart failure. 54 61
12211533 2002
37
[POEMS syndrome with increased vascular endothelial growth factor (VEGF) and multiple osteosclerotic lesion]. 54 61
12170754 2002
38
An autopsy case of POEMS syndrome with a high level of IL-6 and VEGF in the serum and ascitic fluid. 54 61
11929188 2002
39
[POEMS syndrome with increased vascular endothelial growth factor (VEGF)]. 54 61
11917504 2002
40
[Vascular endothelial growth factor and Crow-Fukase syndrome]. 54 61
12235821 2001
41
[A case of polyneuropathy associated with increased levels of vascular endotherial growth factor (VEGF) insera]. 54 61
11993185 2001
42
A case of POEMS syndrome with high concentrations of interleukin-6 in pericardial fluid. 54 61
11489068 2001
43
Increased serum level of vascular endothelial growth factor in Crow-Fukase syndrome. 54 61
11720194 2001
44
Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome. 54 61
11274326 2001
45
[A patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma]. 54 61
11481854 2001
46
VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome. 54 61
11197800 2000
47
Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. 54 61
10882999 2000
48
[POEMS syndrome revealed by a scleroderma-like skin thickening]. 54 61
10717569 2000
49
A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. 54 61
10528660 1999
50
Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. 54 61
10516342 1999

Variations for Poems Syndrome

Expression for Poems Syndrome

Search GEO for disease gene expression data for Poems Syndrome.

Pathways for Poems Syndrome

Pathways related to Poems Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 VEGFA TNFSF11 TNFRSF11B TNF PTX3 IL6
2
Show member pathways
13.75 VEGFA TNFSF11 TNF IL6 IL2 IL1B
3
Show member pathways
13.57 TNFSF11 TNFRSF11B TNF IL6 IL2 IL1B
4
Show member pathways
13.48 VEGFA TNF IL6 IL2 IL1B HGF
5
Show member pathways
13.35 TNFSF11 TNF IL6 IL2 IL1B HGF
6
Show member pathways
13.21 TNFSF11 TNF IL6 IL2 IL1B HGF
7
Show member pathways
13.17 VEGFA TNFSF11 TNFRSF11B TNF IL6 IL2
8
Show member pathways
12.93 VEGFA TNF IL6 IL2 HGF EPO
9
Show member pathways
12.9 VEGFA TNFSF11 TNFRSF11B TNF IL6
10 12.82 VEGFA IL6 IL2 HGF EPO
11
Show member pathways
12.82 VEGFA TNF IL6 IL2 IL1B
12
Show member pathways
12.67 TNF IL6 IL2 IL1B HGF
13
Show member pathways
12.56 TNF IL6 IL2 IL1B
14
Show member pathways
12.55 TNF IL6 IL2 IL1B
15
Show member pathways
12.55 TNF IL6 IL2 IL1B
16
Show member pathways
12.54 TNFSF11 TNFRSF11B TNF IL1B
17 12.52 TNFSF11 TNF IL2 IL1B
18
Show member pathways
12.33 IL6 IL2 EPO CSF3
19
Show member pathways
12.32 TNF IL6 IL1B CSF3
20
Show member pathways
12.32 TNF IL6 IL2 IL1B
21
Show member pathways
12.22 TNF IL6 IL2 IL1B HGF
22
Show member pathways
12.2 TNF IL6 IL2 IL1B
23 12.16 VEGFA TNF IL6 IL1B
24 12.05 VEGFA TNF IL1B
25
Show member pathways
12.04 TNF IL6 IL2 IL1B
26 12.03 VEGFA IL6 HGF
27 12.02 TNFSF11 TNFRSF11B TNF IL1B
28
Show member pathways
12 TNF IL6 IL1B
29 11.98 TNF IL6 IL2 IL1B
30 11.97 TNF IL6 IL2 IL1B
31 11.96 TNF IL6 IL2 EPO CSF3
32 11.95 TNF IL6 IL1B
33 11.93 VEGFA IL6 EPO
34 11.93 VEGFA TNF IL6 IL1B HGF
35 11.89 TNFSF11 TNF IL1B
36 11.89 TNF IL6 IL1B
37 11.88 VEGFA TNF IL6 IL1B
38 11.86 IL6 IL2 EPO
39 11.85 TNF IL6 IL1B EPO CSF3
40 11.8 VEGFA TNFSF11 TNF IL6 IL1B
41 11.78 TNF IL2 IL1B
42 11.75 TNF IL6 IL1B
43 11.74 TNF IL6 IL2 IL1B
44 11.71 TNF IL6 IL2 IL1B
45 11.62 TNF IL6 IL1B
46
Show member pathways
11.57 VEGFA TNF IL6 IL2 IL1B
47 11.56 TNF IL6 IL2
48 11.53 TNF IL2 IL1B
49 11.53 TNF IL6 IL1B CSF3
50 11.51 IL6 IL1B EPO CSF3

GO Terms for Poems Syndrome

Cellular components related to Poems Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 VEGFA TNFSF11 TNFRSF11B TNF PTX3 IL6
2 extracellular space GO:0005615 9.36 VEGFA TNFSF11 TNFRSF11B TNF PTX3 IL6

Biological processes related to Poems Syndrome according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.02 VEGFA IL6 IL2 HGF EPO
2 inflammatory response GO:0006954 9.99 TNF PTX3 IL6 IL1B
3 positive regulation of gene expression GO:0010628 9.99 VEGFA TNFSF11 TNF IL6 IL1B
4 positive regulation of cell proliferation GO:0008284 9.95 VEGFA IL6 IL2 IL1B EPO CSF3
5 MAPK cascade GO:0000165 9.94 TNF IL2 IL1B HGF
6 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IL6 IL1B CSF3
7 immune response GO:0006955 9.88 TNFSF11 TNF IL6 IL2 IL1B CSF3
8 activation of MAPK activity GO:0000187 9.86 TNF IL1B HGF
9 positive regulation of protein kinase B signaling GO:0051897 9.86 TNFSF11 TNF HGF CSF3
10 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 VEGFA TNFSF11 TNF IL6 IL2 IL1B
11 tumor necrosis factor-mediated signaling pathway GO:0033209 9.85 TNFSF11 TNFRSF11B TNF
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 TNFSF11 TNF IL6 IL1B
13 positive regulation of inflammatory response GO:0050729 9.83 TNF IL2 IL1B
14 positive regulation of JNK cascade GO:0046330 9.82 TNFSF11 TNF IL1B
15 positive regulation of MAP kinase activity GO:0043406 9.81 VEGFA TNFSF11 TNF
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.81 VEGFA IL6 HGF CSF3
17 positive regulation of T cell proliferation GO:0042102 9.8 IL6 IL2 IL1B
18 positive regulation of interleukin-6 production GO:0032755 9.79 TNF IL6 IL1B
19 positive regulation of phagocytosis GO:0050766 9.77 TNF PTX3 IL1B
20 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.76 TNF HGF EPO CSF3
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.75 TNF PTX3 IL1B
22 positive regulation of interferon-gamma production GO:0032729 9.74 TNF IL2 IL1B
23 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.73 VEGFA TNF IL6 CSF3
24 positive regulation of protein phosphorylation GO:0001934 9.72 VEGFA TNF IL2 IL1B HGF
25 positive regulation of chemokine production GO:0032722 9.71 TNF IL6
26 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.71 TNF IL1B
27 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.7 VEGFA IL1B
28 mammary gland alveolus development GO:0060749 9.7 VEGFA TNFSF11
29 negative regulation of lipid catabolic process GO:0050995 9.7 TNF IL1B
30 astrocyte activation GO:0048143 9.7 TNF IL1B
31 negative regulation of neurogenesis GO:0050768 9.7 TNF IL6 IL1B
32 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.69 TNF IL1B
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 TNF IL1B
34 regulation of osteoclast differentiation GO:0045670 9.68 TNFSF11 TNF
35 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.68 TNF IL1B
36 negative regulation of bone resorption GO:0045779 9.67 TNFRSF11B IL6
37 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL6 IL2
38 cardiac muscle fiber development GO:0048739 9.67 VEGFA MYOM2
39 positive regulation of glial cell proliferation GO:0060252 9.67 TNF IL6 IL1B
40 positive regulation of chemokine biosynthetic process GO:0045080 9.66 TNF IL1B
41 response to salt stress GO:0009651 9.66 TNF EPO
42 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
43 regulation of establishment of endothelial barrier GO:1903140 9.64 TNF IL1B
44 positive regulation of fever generation GO:0031622 9.61 TNF IL1B
45 sequestering of triglyceride GO:0030730 9.61 TNF IL1B
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.55 TNF IL1B
47 positive regulation of DNA-binding transcription factor activity GO:0051091 9.55 TNFSF11 TNF IL6 IL1B CSF3
48 positive regulation of neuroinflammatory response GO:0150078 9.54 TNF IL6 IL1B
49 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 VEGFA TNF IL6 IL2 EPO
50 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA TNFSF11 TNF IL6 IL2 IL1B

Molecular functions related to Poems Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 VEGFA IL6 IL2 HGF CSF3
2 cytokine activity GO:0005125 9.28 VEGFA TNFSF11 TNFRSF11B TNF IL6 IL2

Sources for Poems Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....